New National Survey Finds Nearly Half of US Adults Admit to Not Washing Their Hands at Key Moments
1 out of 5 (20%) admit to not washing their hands, even though handwashing can help prevent approximately 80% of infectious diseases
BETHESDA, Md., May 5, 2025 /PRNewswire/ -- Today, on World Hand Hygiene Day, the National Foundation for Infectious Diseases (NFID) is launching the Hands In For Handwashing campaign to raise awareness about the importance of handwashing to help stop the spread of infectious diseases. The campaign includes the 2025 NFID State of Handwashing Report, based on a new national survey of US adult handwashing knowledge and behaviors.
The report offers unique insights into where, when, and why US adults are most likely to wash their hands, and when they forget or choose not to do so. Following the worst influenza (flu) season in more than a decade and several norovirus outbreaks across the US, the NFID report reveals that while US adults say they know how to wash their hands properly, their habits often suggest otherwise.
Key survey findings:
'Given the importance of handwashing in infectious disease prevention, the stakes are high—improving hand hygiene can help improve health for all,' said NFID Medical Director Robert H. Hopkins, Jr., MD. 'While handwashing is an important strategy for disease prevention, and should be complementary to vaccination, it is a critical and often overlooked tool.' Estimates show that if everyone routinely washed their hands, about 1 million lives could be saved around the world each year.
According to the survey, 55% of US adults wash their hands primarily to stay healthy and avoid getting sick. In addition, 68% of respondents said that avoiding spreading germs to others was among their top 3 reasons for handwashing, showing concern for protecting others in the community.
'Proper handwashing puts the power of health in our own hands,' said NFID Immediate Past-President Patricia A. Stinchfield, RN, MS, CPNP. 'Handwashing is an easy and effective way to prioritize your health and the health of those around you.'
For some, handwashing is a seasonal behavior–1 in 4 (26%) respondents reported washing their hands more frequently in the fall and winter, even though germs can spread throughout the year. The survey also found that 33% of respondents report washing their hands more now than they did during the COVID-19 pandemic.
As part of the campaign, NFID is also hitting the road with a Clean Hands Caravan, a mobile handwashing station to make it easier for people to wash their hands in places where germs can spread.
'The caravan was created to make handwashing accessible and visible during key moments in everyday life when it is important to wash hands,' said NFID Chief Executive Officer Marla Dalton, PE, CAE. 'We wanted to grab people's attention with vibrant colors, eye-catching graphics, and memorable slogans to bring some excitement to an important but sometimes overlooked habit taught in kindergarten—washing your hands.'
The Clean Hands Caravan tour launched at the Washington Spirit soccer game in Washington, DC on May 2, 2025. Additional tour stops include the World Barbeque Cooking Contest in Memphis, TN, from May 14-17, 2025, and the Atlanta Jazz Festival in Atlanta, GA, from May 24-26, 2025. 'NFID encourages everyone to wash their hands to help stop the spread of infectious diseases, and we encourage organizations to join the Hands In For Handwashing movement to support healthier lives for all,' Dalton said.
For more information about the 2025 NFID State of Handwashing report, and to access handwashing resources throughout the year, visit: www.nfid.org/handwashing
About the National Foundation for Infectious Diseases
Founded in 1973, the National Foundation for Infectious Diseases (NFID) is a non-profit 501(c)(3) organization dedicated to educating and engaging the public, communities, and healthcare professionals about infectious diseases across the lifespan. NFID has a 4-star rating from Charity Navigator and has earned a Platinum transparency seal from Candid/GuideStar. For more information, visit www.nfid.org.
About the Survey
The survey was funded by NFID and conducted by NORC at the University of Chicago as part of the AmeriSpeak Omnibus®, a monthly survey using the NORC probability-based panel designed to be representative of the US household population. The US survey received responses from 3,587 respondents from all 50 states and the District of Columbia via online and telephone interviews using landlines and cell phones. Data was collected in November and December 2024 and March 2025. The margin of sampling error is ±2 percentage points for all respondents.
Contact: Ryan Horey, [email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/new-national-survey-finds-nearly-half-of-us-adults-admit-to-not-washing-their-hands-at-key-moments-302445548.html
SOURCE National Foundation for Infectious Diseases
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Implantica publishes Interim Report January - June 2025 (Q2)
VADUZ, Liechtenstein, Aug. 14, 2025 /PRNewswire/ -- Transforming Clinical Excellence of RefluxStop® into Strategic Market Momentum Significant events in the second quarter of 2025 FDA PMA Submission Completed - Submitted third and final module of the U.S. FDA pre-market approval (PMA) application for RefluxStop®, including responses to questions on the second module; Feedback on module 3 expected in the near-term Produced and completed initial testing on new multi-cavity production tool for RefluxStop® to support launch of manufacturing in U.S. and manage ramp-up of U.S. production (pending FDA approval) Additional preparations for U.S. market launch (pending FDA approval) included U.S. payer and reimbursement activities, finalizing new production facility of RefluxStop® in U.S. and launching our RCT (randomized clinical trial), as a heavyweight cornerstone in building global leadership in acid reflux care Positive NICE Guidance in the UK - UK's National Institute for Health and Care Excellence (NICE) issued positive guidance for the use of RefluxStop® in NHS hospitals for patients with ineffective esophageal motility (IOM/IEM), potentially transforming treatment access for millions and influencing global policy Significant events after the end of the period Landmark 5-Year Clinical Study Results - Two peer-reviewed articles were published in Surgical Endoscopy on our pivotal study results; one publication confirmed outstanding long-term safety and effectiveness outcomes, and the second publication highlighted RefluxStop®'s excellent outcomes in food passageway-related sequelae, which is common in standard of care Randomized Clinical Trial (RCT) Launch - First RCT comparing RefluxStop® with Nissen fundoplication; patient recruitment underway accumulating patients across participating hospitals. While this trial preparation led to a 20% year-on-year revenue decline for Q2, the impact is expected to ease once study recruitment stabilizes Spanish Market Expansion - Three new hospitals added, totaling 19 centers offering RefluxStop® in Spain, with a healthcare sytem receptive for new and better patient care, which is a fantastic launch since 2023 First UK National Users Meeting - Convened 21 top anti-reflux experts to discuss real-world results, operating technique and the opportunities arising from NICE's positive recommendation Financial summary second quarter 2025 Net sales decreased 22% to TEUR 433 (554) due to the launch of the randomized clinical trial with surgeons accumulating patients for the trial. Adjusted gross margin amounted to 90% (91%). Operating loss (EBIT) decreased to TEUR 4,525 (5,869). Loss after tax decreased to TEUR 5,448 (6,431). Basic and diluted loss per Class A share amounted to EUR 0.08 (0.09). Cash and short-term investments as at the end of the period of MEUR 56.3. First six months Net sales increased 2% to TEUR 1,178 (1,150). Adjusted gross margin amounted to 94% (91%). Operating loss (EBIT) decreased to TEUR 8,698 (12,956). Loss after tax decreased to TEUR 8,212 (9,903). Basic and diluted loss per Class A share amounted to EUR 0.12 (0.14). Telephone conference Implantica will hold a teleconference on 14 August 2025 at 15:00 (CEST) with Peter Forsell (CEO), Andreas Öhrnberg (CFO), and Nicole Pehrsson (Chief Corporate Affairs Officer). Please see the dial-in details below to join the conference: Webcast If you wish to participate via webcast, please use the following link: Dial-in Dial-in numbers to the teleconference will be received by registering on the link below. After the registration, you will be provided phone numbers and a conference ID to access the conference. For further information, please contact:Nicole Pehrsson, Chief Corporate Affairs OfficerTelephone (CH): +41 (0)79 335 09 Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm. The company's Certified Adviser is FNCA Sweden AB, info@ This information is information that Implantica AG is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-08-14 08:00 CEST. About Implantica: Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop®, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit for further information. This information was brought to you by Cision The following files are available for download: Implantica Q2 2025_ENG Implantica publishes Interim Report Jan - Jun 2025 Q2 View original content:
UPI
an hour ago
- UPI
CDC director: Misinformation 'lead to deadly consequence" in Atlanta
The U.S. Centers for Disease Control and Prevention headquarters in Atlanta was attacked by a gunman on Friday. File Photo by Erike S. Lesser/EPA Aug. 13 (UPI) -- The director of the Centers for Disease Control and Prevention told employees about the dangers of misinformation, four days after a suspected gunman shot at the agency's headquarters in Atlanta, claiming the COVID-19 vaccine made him sick. On Tuesday, Susan Monarez met with staffers virtually and then sent a note to all 10,000 employees nationwide, obtained by ABC News. Staffers at the headquarters have been working remotely since the attack on Friday. "The dangers of misinformation and its promulgation has now led to deadly consequences," she wrote. "I will work to restore trust in public health to those who have lost it -- through science, evidence and clarity of purpose. I will need your help." The comments were slightly different than those during her staff meeting in which she said: "Public health should never be under attack. We know that misinformation can be dangerous." She said the health agency can rebuild trust with "rational evidence-based discourse" with "compassion and understanding." Dr. Paul Offit, the director of the Vaccine Education Center at Children's Hospital of Pennsylvania, told NBC News: "The irony is her boss is the biggest spreader of misinformation." Robert F. Kennedy Jr. is secretary of the Health and Human Services, which oversees the CDC. In 2021, during the pandemic, Kennedy described the shot as the "deadliest vaccine ever made" after he filed a citizens' petition requesting that the Food and Drug Administration end emergency authorization. Last week, Kennedy announced that HHS was moving to terminate $500 million in contracts to develop vaccines using mRNA technology, which was used to develop the COVID-19 vaccine in 2020. "After reviewing the science and consulting top experts at NIH [National Institutes of Health] and FDA, HHS has determined that mRNA technology poses more risks than benefits for these respiratory viruses," The American Medical Association backs mRNA vaccine research and the CDC still says on its website: "During the COVID-19 pandemic, COVID-19 vaccines underwent the most intensive safety analysis in U.S. history." Health officials have denounced skepticism of the research, noting the COVID-19 vaccine saved millions of lives in the United States. "The Covid pandemic showed us what's possible when science moves fast," Rick Bright, who directed the Biomedical Advanced Research and Development from 2016 to 2020, told NBC News. "Dismantling that momentum now is like disbanding the fire department because the fire's out." As head of the HHS, he has updated COVID-19 vaccine recommendations for the fall to be restricted to older adults and those with underlying health conditions. He also doesn't want children to get the shots. On Monday, Kennedy toured the CDC campus in Atlanta and met with the widow of the one person slain in the attack, DeKalb County Police Officer David Rose. He toured with Monarez and HHS Deputy Secretary Jim O'Neill. "He offered his deepest condolences and reaffirmed the agency's commitment to honoring officer Rose's bravery, sacrifice and service to the nation," HHS said. Today I traveled to Atlanta in the wake of the heartbreaking shooting at the CDC's Roybal Campus that took the life of DeKalb County Police Officer David Rose. @POTUS and the entire administration are deeply saddened by this tragic loss. We stand with Officer Rose's wife, his two... Secretary Kennedy (@SecKennedy) August 11, 2025 Since the attack, the union representing CDC workers condemned the lack of support from top officials. "This leadership is critical in reinforcing public trust and ensuring that accurate, science-based information prevails," the union said Sunday. "This condemnation is necessary to help prevent violence against scientists that may be incited by such disinformation." The American Federation of Government Employees Local 2883, which represents more than 2,000 CDC workers, said in a statement Sunday that the attack "was not random and it compounds months of mistreatment, neglect and vilification that CDC staff have endured." The union also said: "The deliberate targeting of CDC through this violent act is deeply disturbing, completely unacceptable and an attack on every public servant." The father of the suspected gunman, 30-year-old Patrick Joseph White, reportedly told authorities he targeted the CDC over health problems he blamed on the COVID-19 vaccine. He said the shot made him depressed and suicidal. He was fatally shot by police after around 200 bullets struck the six buildings. Five firearms were recovered. "All indications are that this was an isolated event involving one individual," Jeff Williams, the deputy secretary of the CDC's Office of Safety, Security and Asset Management, said during the staff meeting Tuesday.
Time Business News
3 hours ago
- Time Business News
Hygiene Tech Meets Healing Proteins
Hospital-acquired infections can be caused by the cross-infection from surface and skin of patient, equipment, and healthcare staff. Various types of products and services are available to control hospital-acquired infections such as sterilization, cleaning & disinfection products, protective barriers, and endoscope reprocessing products. Increase in awareness regarding personal hygiene after COVID-19 is a major factor to boost the Hospital Infection Prevention and Control growth. Growth factors, proteins or peptides found in nature, are important for the control of cell actions like growth, specialization, movement, and survival. They attach to certain receptors on cell surfaces, which starts signals inside the cells that change how they act. Growth factors are needed for body functions such as development in embryos, healing wounds, fixing tissues, and immune reactions. Key Growth Drivers and Opportunities High Cases of Hospital Acquired Infections: Hospital-acquired infections (HAIs) remain a major risk to patient safety and healthcare results around the world. These infections, often caused by bacteria like Staphylococcus aureus, Clostridium difficile, and Escherichia coli, usually happen because of long hospital stays, surgeries, poor infection control, and antibiotic resistance. Those in intensive care, people with weak immune systems, and those having surgery are at risk. HAIs raise sickness and death rates; these also cause higher medical costs and longer stays in hospitals. Growing Geriatric Population: The growing geriatric population significantly contributes to the rise in hospital-acquired infections, as older adults often have weakened immune systems and require frequent medical care or hospitalization. This increases their vulnerability to infections, driving the demand for effective hospital infection prevention and control measures. As a result, healthcare facilities are investing more in disinfection, protective equipment, and sterilization solutions to ensure patient safety and reduce infection risks in aging populations. Challenges Failure of end-users to follow infection prevention rules limits how well hospital infection control works. When staff, patients, or support people don't follow hygiene rules—such as washing hands, sterilizing tools, or using safety gear— the risk of contamination and infections rises. Innovation and Expansion NAVTA & Virox Launch Free Infection Control Training for Safer Vet Care In March 2023, (National Association of Veterinary Technicians in America) NAVTA, Virox launch certificate program in infection prevention, to advance best practices in infection prevention. This program is a free online program designed to provide professionals with the knowledge needed to reduce the risk of spreading infection and create a safer workplace for their team, patients, and clients. NeoIPC Unveils Toolkit to Shield Newborns from Hospital Infections In November 2023, The NeoIPC Consortium announced the launch of a new surveillance toolkit to help neonatal intensive care units (NICUs) track and prevent hospital-acquired infections (HAIs) in high-risk newborns, including very preterm infants. This toolkit aims to standardize how infections are tracked in Newborn Intensive Care Units (NICUs) to allow for improved data gathering and assessment. It has tools, training, and reporting forms made for newborn care locations. By helping with early detection and response, this project hopes to lower infection rates and improve results for fragile newborns. Inventive Sparks, Expanding Markets The key players operating the hospital infection prevention and control market includes, 3M Company, Crosstex International, Inc., Johnson & Johnson, Belimed AG, among others. Worldwide business aims center on encouraging lasting growth, improving health and safety for the public, and boosting progress through cooperation. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
